Global Melanoma Therapeutics Market
Global Melanoma Therapeutics Market

Melanoma Therapeutics Comprehensive Study by Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic, Zelboraf, Imlygic, Generics), Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy), Stages (Stage 0 (Melanoma in Situ), Stage I, Stage II, Stage III, Stage IV), Cancer Type (Nodular Melanoma, Acral Lentiginous Melanoma, Superficial Spreading Melanoma, Others), Diagnosis (Ultrasound, Blood Tests, Dermatoscopy, CT scan, Others) Players and Region - Global Market Outlook to 2024

Melanoma Therapeutics Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

May 2019 Edition 241 Pages 187 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Melanoma Therapeutics Market Scope
Melanoma is defined as the form of skin cancer which arises when pigment-producing cells. In addition, most pigment cells are found in the skin and it can also occur in the eyes as well as other parts of the body such as intestines, among others. It mostly occurs when increasing for people under the age of 40 years, especially women and overexposure to the sun. In 2017, according to an article published by national cancer institute (United States), more than 87,110 new melanomas were anticipated to be diagnosed in 2017, and more than 9,730 people were predictable to die of melanoma. Hence, the rising number of patients due to melanomas disease, increasing incidence of cancer, especially skin cancers are some of the major factors which propel the growth of the market in the future. The market for the melanoma therapeutics is expected to register a CAGR of over 12.23% during the forecast period

The market study is being classified and major geographies with country level break-up.

The melanoma therapeutics market is highly fragmented in nature with a large number of international as well as regional players operating in the market. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Melanoma Therapeutics market throughout the predicted period.

AstraZeneca plc (United Kingdom), Amgen, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (United States), Novartis International AG (Switzerland), Merck & Co., Inc. (United States), Daiichi Sankyo Company, Limited (Japan), AB Sciences (France) and Vical, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Pfizer, Inc. (United States), GlaxoSmithKline, plc. (United Kingdom) and Eisai Co., Ltd. (Japan).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Melanoma Therapeutics market by Type, Application and Region.

On the basis of geography, the market of Melanoma Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drugs, the sub-segment i.e. Opdivo will boost the Melanoma Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapy, the sub-segment i.e. Chemotherapy will boost the Melanoma Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Stages, the sub-segment i.e. Stage 0 (Melanoma in Situ) will boost the Melanoma Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Cancer Type, the sub-segment i.e. Nodular Melanoma will boost the Melanoma Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Ultrasound will boost the Melanoma Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In July 2016, the Bristol-Myers Squibb (United States) Company has acquired Cormorant Pharmaceuticals AB (Sweden) Company in order to broaden its immuno-oncology pipeline. Hence, it will affect the growth of the market in the future.


Market Trend
  • Rising Prevalence of Skin Disorders such as skin cancer, skin infections, and skin allergies

Market Drivers
  • Increased Awareness Regarding the Treatment of Melanoma
  • Increasing Prevalence of Melanoma and Technical Advancements

Opportunities
  • Rising Demand from Emerging Economics such as China and India
  • Government Initiatives to Expand the Melanoma Therapeutics Market

Restraints
  • High Costs Incurred owing to Combination Treatments and Limited Reimbursement

Challenges
  • Lack of Awareness regarding Melanoma Therapeutics in Some Developing Regions


Key Target Audience
Manufacturers of Melanoma Therapeutics Products, Research and Development (R&D) Companies, Research Organization, Federal Agencies and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Drugs
  • Opdivo
  • Yervoy
  • Mekinist+Tafinlar
  • Keytruda
  • Cotellic
  • Zelboraf
  • Imlygic
  • Generics

By Therapy
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Radiation Therapy

By Stages
  • Stage 0 (Melanoma in Situ)
  • Stage I
  • Stage II
  • Stage III
  • Stage IV

By Cancer Type
  • Nodular Melanoma
  • Acral Lentiginous Melanoma
  • Superficial Spreading Melanoma
  • Others

By Diagnosis
  • Ultrasound
  • Blood Tests
  • Dermatoscopy
  • CT scan
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Awareness Regarding the Treatment of Melanoma
      • 3.2.2. Increasing Prevalence of Melanoma and Technical Advancements
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness regarding Melanoma Therapeutics in Some Developing Regions
    • 3.4. Market Trends
      • 3.4.1. Rising Prevalence of Skin Disorders such as skin cancer, skin infections, and skin allergies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Melanoma Therapeutics, by Drugs, Therapy, Stages, Cancer Type, Diagnosis and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Melanoma Therapeutics (Value)
      • 5.2.1. Global Melanoma Therapeutics by: Drugs (Value)
        • 5.2.1.1. Opdivo
        • 5.2.1.2. Yervoy
        • 5.2.1.3. Mekinist+Tafinlar
        • 5.2.1.4. Keytruda
        • 5.2.1.5. Cotellic
        • 5.2.1.6. Zelboraf
        • 5.2.1.7. Imlygic
        • 5.2.1.8. Generics
      • 5.2.2. Global Melanoma Therapeutics by: Therapy (Value)
        • 5.2.2.1. Chemotherapy
        • 5.2.2.2. Immunotherapy
        • 5.2.2.3. Targeted Therapy
        • 5.2.2.4. Radiation Therapy
      • 5.2.3. Global Melanoma Therapeutics by: Stages (Value)
        • 5.2.3.1. Stage 0 (Melanoma in Situ)
        • 5.2.3.2. Stage I
        • 5.2.3.3. Stage II
        • 5.2.3.4. Stage III
        • 5.2.3.5. Stage IV
      • 5.2.4. Global Melanoma Therapeutics by: Cancer Type (Value)
        • 5.2.4.1. Nodular Melanoma
        • 5.2.4.2. Acral Lentiginous Melanoma
        • 5.2.4.3. Superficial Spreading Melanoma
        • 5.2.4.4. Others
      • 5.2.5. Global Melanoma Therapeutics by: Diagnosis (Value)
        • 5.2.5.1. Ultrasound
        • 5.2.5.2. Blood Tests
        • 5.2.5.3. Dermatoscopy
        • 5.2.5.4. CT scan
        • 5.2.5.5. Others
      • 5.2.6. Global Melanoma Therapeutics Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Melanoma Therapeutics (Volume)
      • 5.3.1. Global Melanoma Therapeutics by: Drugs (Volume)
        • 5.3.1.1. Opdivo
        • 5.3.1.2. Yervoy
        • 5.3.1.3. Mekinist+Tafinlar
        • 5.3.1.4. Keytruda
        • 5.3.1.5. Cotellic
        • 5.3.1.6. Zelboraf
        • 5.3.1.7. Imlygic
        • 5.3.1.8. Generics
      • 5.3.2. Global Melanoma Therapeutics by: Therapy (Volume)
        • 5.3.2.1. Chemotherapy
        • 5.3.2.2. Immunotherapy
        • 5.3.2.3. Targeted Therapy
        • 5.3.2.4. Radiation Therapy
      • 5.3.3. Global Melanoma Therapeutics by: Stages (Volume)
        • 5.3.3.1. Stage 0 (Melanoma in Situ)
        • 5.3.3.2. Stage I
        • 5.3.3.3. Stage II
        • 5.3.3.4. Stage III
        • 5.3.3.5. Stage IV
      • 5.3.4. Global Melanoma Therapeutics by: Cancer Type (Volume)
        • 5.3.4.1. Nodular Melanoma
        • 5.3.4.2. Acral Lentiginous Melanoma
        • 5.3.4.3. Superficial Spreading Melanoma
        • 5.3.4.4. Others
      • 5.3.5. Global Melanoma Therapeutics by: Diagnosis (Volume)
        • 5.3.5.1. Ultrasound
        • 5.3.5.2. Blood Tests
        • 5.3.5.3. Dermatoscopy
        • 5.3.5.4. CT scan
        • 5.3.5.5. Others
      • 5.3.6. Global Melanoma Therapeutics Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Melanoma Therapeutics (Price)
  • 6. Melanoma Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amgen, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bristol-Myers Squibb Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis International AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co., Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Daiichi Sankyo Company, Limited (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AB Sciences (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Vical, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Melanoma Therapeutics Sale, by Drugs, Therapy, Stages, Cancer Type, Diagnosis and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Melanoma Therapeutics (Value)
      • 7.2.1. Global Melanoma Therapeutics by: Drugs (Value)
        • 7.2.1.1. Opdivo
        • 7.2.1.2. Yervoy
        • 7.2.1.3. Mekinist+Tafinlar
        • 7.2.1.4. Keytruda
        • 7.2.1.5. Cotellic
        • 7.2.1.6. Zelboraf
        • 7.2.1.7. Imlygic
        • 7.2.1.8. Generics
      • 7.2.2. Global Melanoma Therapeutics by: Therapy (Value)
        • 7.2.2.1. Chemotherapy
        • 7.2.2.2. Immunotherapy
        • 7.2.2.3. Targeted Therapy
        • 7.2.2.4. Radiation Therapy
      • 7.2.3. Global Melanoma Therapeutics by: Stages (Value)
        • 7.2.3.1. Stage 0 (Melanoma in Situ)
        • 7.2.3.2. Stage I
        • 7.2.3.3. Stage II
        • 7.2.3.4. Stage III
        • 7.2.3.5. Stage IV
      • 7.2.4. Global Melanoma Therapeutics by: Cancer Type (Value)
        • 7.2.4.1. Nodular Melanoma
        • 7.2.4.2. Acral Lentiginous Melanoma
        • 7.2.4.3. Superficial Spreading Melanoma
        • 7.2.4.4. Others
      • 7.2.5. Global Melanoma Therapeutics by: Diagnosis (Value)
        • 7.2.5.1. Ultrasound
        • 7.2.5.2. Blood Tests
        • 7.2.5.3. Dermatoscopy
        • 7.2.5.4. CT scan
        • 7.2.5.5. Others
      • 7.2.6. Global Melanoma Therapeutics Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Melanoma Therapeutics (Volume)
      • 7.3.1. Global Melanoma Therapeutics by: Drugs (Volume)
        • 7.3.1.1. Opdivo
        • 7.3.1.2. Yervoy
        • 7.3.1.3. Mekinist+Tafinlar
        • 7.3.1.4. Keytruda
        • 7.3.1.5. Cotellic
        • 7.3.1.6. Zelboraf
        • 7.3.1.7. Imlygic
        • 7.3.1.8. Generics
      • 7.3.2. Global Melanoma Therapeutics by: Therapy (Volume)
        • 7.3.2.1. Chemotherapy
        • 7.3.2.2. Immunotherapy
        • 7.3.2.3. Targeted Therapy
        • 7.3.2.4. Radiation Therapy
      • 7.3.3. Global Melanoma Therapeutics by: Stages (Volume)
        • 7.3.3.1. Stage 0 (Melanoma in Situ)
        • 7.3.3.2. Stage I
        • 7.3.3.3. Stage II
        • 7.3.3.4. Stage III
        • 7.3.3.5. Stage IV
      • 7.3.4. Global Melanoma Therapeutics by: Cancer Type (Volume)
        • 7.3.4.1. Nodular Melanoma
        • 7.3.4.2. Acral Lentiginous Melanoma
        • 7.3.4.3. Superficial Spreading Melanoma
        • 7.3.4.4. Others
      • 7.3.5. Global Melanoma Therapeutics by: Diagnosis (Volume)
        • 7.3.5.1. Ultrasound
        • 7.3.5.2. Blood Tests
        • 7.3.5.3. Dermatoscopy
        • 7.3.5.4. CT scan
        • 7.3.5.5. Others
      • 7.3.6. Global Melanoma Therapeutics Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Melanoma Therapeutics (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Melanoma Therapeutics: by Drugs(USD Million)
  • Table 2. Melanoma Therapeutics Opdivo , by Region USD Million (2013-2018)
  • Table 3. Melanoma Therapeutics Yervoy , by Region USD Million (2013-2018)
  • Table 4. Melanoma Therapeutics Mekinist+Tafinlar , by Region USD Million (2013-2018)
  • Table 5. Melanoma Therapeutics Keytruda , by Region USD Million (2013-2018)
  • Table 6. Melanoma Therapeutics Cotellic , by Region USD Million (2013-2018)
  • Table 7. Melanoma Therapeutics Zelboraf , by Region USD Million (2013-2018)
  • Table 8. Melanoma Therapeutics Imlygic , by Region USD Million (2013-2018)
  • Table 9. Melanoma Therapeutics Generics , by Region USD Million (2013-2018)
  • Table 10. Melanoma Therapeutics: by Therapy(USD Million)
  • Table 11. Melanoma Therapeutics Chemotherapy , by Region USD Million (2013-2018)
  • Table 12. Melanoma Therapeutics Immunotherapy , by Region USD Million (2013-2018)
  • Table 13. Melanoma Therapeutics Targeted Therapy , by Region USD Million (2013-2018)
  • Table 14. Melanoma Therapeutics Radiation Therapy , by Region USD Million (2013-2018)
  • Table 15. Melanoma Therapeutics: by Stages(USD Million)
  • Table 16. Melanoma Therapeutics Stage 0 (Melanoma in Situ) , by Region USD Million (2013-2018)
  • Table 17. Melanoma Therapeutics Stage I , by Region USD Million (2013-2018)
  • Table 18. Melanoma Therapeutics Stage II , by Region USD Million (2013-2018)
  • Table 19. Melanoma Therapeutics Stage III , by Region USD Million (2013-2018)
  • Table 20. Melanoma Therapeutics Stage IV , by Region USD Million (2013-2018)
  • Table 21. Melanoma Therapeutics: by Cancer Type(USD Million)
  • Table 22. Melanoma Therapeutics Nodular Melanoma , by Region USD Million (2013-2018)
  • Table 23. Melanoma Therapeutics Acral Lentiginous Melanoma , by Region USD Million (2013-2018)
  • Table 24. Melanoma Therapeutics Superficial Spreading Melanoma , by Region USD Million (2013-2018)
  • Table 25. Melanoma Therapeutics Others , by Region USD Million (2013-2018)
  • Table 26. Melanoma Therapeutics: by Diagnosis(USD Million)
  • Table 27. Melanoma Therapeutics Ultrasound , by Region USD Million (2013-2018)
  • Table 28. Melanoma Therapeutics Blood Tests , by Region USD Million (2013-2018)
  • Table 29. Melanoma Therapeutics Dermatoscopy , by Region USD Million (2013-2018)
  • Table 30. Melanoma Therapeutics CT scan , by Region USD Million (2013-2018)
  • Table 31. Melanoma Therapeutics Others , by Region USD Million (2013-2018)
  • Table 32. South America Melanoma Therapeutics, by Country USD Million (2013-2018)
  • Table 33. South America Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 34. South America Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 35. South America Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 36. South America Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 37. South America Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 38. Brazil Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 39. Brazil Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 40. Brazil Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 41. Brazil Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 42. Brazil Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 43. Argentina Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 44. Argentina Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 45. Argentina Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 46. Argentina Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 47. Argentina Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 48. Rest of South America Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 49. Rest of South America Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 50. Rest of South America Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 51. Rest of South America Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 52. Rest of South America Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 53. Asia Pacific Melanoma Therapeutics, by Country USD Million (2013-2018)
  • Table 54. Asia Pacific Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 55. Asia Pacific Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 56. Asia Pacific Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 57. Asia Pacific Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 58. Asia Pacific Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 59. China Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 60. China Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 61. China Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 62. China Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 63. China Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 64. Japan Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 65. Japan Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 66. Japan Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 67. Japan Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 68. Japan Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 69. India Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 70. India Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 71. India Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 72. India Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 73. India Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 74. South Korea Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 75. South Korea Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 76. South Korea Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 77. South Korea Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 78. South Korea Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 79. Taiwan Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 80. Taiwan Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 81. Taiwan Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 82. Taiwan Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 83. Taiwan Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 84. Australia Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 85. Australia Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 86. Australia Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 87. Australia Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 88. Australia Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 89. Rest of Asia-Pacific Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 90. Rest of Asia-Pacific Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 91. Rest of Asia-Pacific Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 92. Rest of Asia-Pacific Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 93. Rest of Asia-Pacific Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 94. Europe Melanoma Therapeutics, by Country USD Million (2013-2018)
  • Table 95. Europe Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 96. Europe Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 97. Europe Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 98. Europe Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 99. Europe Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 100. Germany Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 101. Germany Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 102. Germany Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 103. Germany Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 104. Germany Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 105. France Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 106. France Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 107. France Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 108. France Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 109. France Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 110. Italy Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 111. Italy Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 112. Italy Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 113. Italy Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 114. Italy Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 115. United Kingdom Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 116. United Kingdom Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 117. United Kingdom Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 118. United Kingdom Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 119. United Kingdom Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 120. Netherlands Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 121. Netherlands Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 122. Netherlands Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 123. Netherlands Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 124. Netherlands Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 125. Rest of Europe Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 126. Rest of Europe Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 127. Rest of Europe Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 128. Rest of Europe Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 129. Rest of Europe Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 130. MEA Melanoma Therapeutics, by Country USD Million (2013-2018)
  • Table 131. MEA Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 132. MEA Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 133. MEA Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 134. MEA Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 135. MEA Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 136. Middle East Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 137. Middle East Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 138. Middle East Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 139. Middle East Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 140. Middle East Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 141. Africa Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 142. Africa Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 143. Africa Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 144. Africa Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 145. Africa Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 146. North America Melanoma Therapeutics, by Country USD Million (2013-2018)
  • Table 147. North America Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 148. North America Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 149. North America Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 150. North America Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 151. North America Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 152. United States Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 153. United States Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 154. United States Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 155. United States Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 156. United States Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 157. Canada Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 158. Canada Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 159. Canada Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 160. Canada Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 161. Canada Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 162. Mexico Melanoma Therapeutics, by Drugs USD Million (2013-2018)
  • Table 163. Mexico Melanoma Therapeutics, by Therapy USD Million (2013-2018)
  • Table 164. Mexico Melanoma Therapeutics, by Stages USD Million (2013-2018)
  • Table 165. Mexico Melanoma Therapeutics, by Cancer Type USD Million (2013-2018)
  • Table 166. Mexico Melanoma Therapeutics, by Diagnosis USD Million (2013-2018)
  • Table 167. Melanoma Therapeutics Sales: by Drugs(k Tons)
  • Table 168. Melanoma Therapeutics Sales Opdivo , by Region k Tons (2013-2018)
  • Table 169. Melanoma Therapeutics Sales Yervoy , by Region k Tons (2013-2018)
  • Table 170. Melanoma Therapeutics Sales Mekinist+Tafinlar , by Region k Tons (2013-2018)
  • Table 171. Melanoma Therapeutics Sales Keytruda , by Region k Tons (2013-2018)
  • Table 172. Melanoma Therapeutics Sales Cotellic , by Region k Tons (2013-2018)
  • Table 173. Melanoma Therapeutics Sales Zelboraf , by Region k Tons (2013-2018)
  • Table 174. Melanoma Therapeutics Sales Imlygic , by Region k Tons (2013-2018)
  • Table 175. Melanoma Therapeutics Sales Generics , by Region k Tons (2013-2018)
  • Table 176. Melanoma Therapeutics Sales: by Therapy(k Tons)
  • Table 177. Melanoma Therapeutics Sales Chemotherapy , by Region k Tons (2013-2018)
  • Table 178. Melanoma Therapeutics Sales Immunotherapy , by Region k Tons (2013-2018)
  • Table 179. Melanoma Therapeutics Sales Targeted Therapy , by Region k Tons (2013-2018)
  • Table 180. Melanoma Therapeutics Sales Radiation Therapy , by Region k Tons (2013-2018)
  • Table 181. Melanoma Therapeutics Sales: by Stages(k Tons)
  • Table 182. Melanoma Therapeutics Sales Stage 0 (Melanoma in Situ) , by Region k Tons (2013-2018)
  • Table 183. Melanoma Therapeutics Sales Stage I , by Region k Tons (2013-2018)
  • Table 184. Melanoma Therapeutics Sales Stage II , by Region k Tons (2013-2018)
  • Table 185. Melanoma Therapeutics Sales Stage III , by Region k Tons (2013-2018)
  • Table 186. Melanoma Therapeutics Sales Stage IV , by Region k Tons (2013-2018)
  • Table 187. Melanoma Therapeutics Sales: by Cancer Type(k Tons)
  • Table 188. Melanoma Therapeutics Sales Nodular Melanoma , by Region k Tons (2013-2018)
  • Table 189. Melanoma Therapeutics Sales Acral Lentiginous Melanoma , by Region k Tons (2013-2018)
  • Table 190. Melanoma Therapeutics Sales Superficial Spreading Melanoma , by Region k Tons (2013-2018)
  • Table 191. Melanoma Therapeutics Sales Others , by Region k Tons (2013-2018)
  • Table 192. Melanoma Therapeutics Sales: by Diagnosis(k Tons)
  • Table 193. Melanoma Therapeutics Sales Ultrasound , by Region k Tons (2013-2018)
  • Table 194. Melanoma Therapeutics Sales Blood Tests , by Region k Tons (2013-2018)
  • Table 195. Melanoma Therapeutics Sales Dermatoscopy , by Region k Tons (2013-2018)
  • Table 196. Melanoma Therapeutics Sales CT scan , by Region k Tons (2013-2018)
  • Table 197. Melanoma Therapeutics Sales Others , by Region k Tons (2013-2018)
  • Table 198. South America Melanoma Therapeutics Sales, by Country k Tons (2013-2018)
  • Table 199. South America Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 200. South America Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 201. South America Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 202. South America Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 203. South America Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 204. Brazil Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 205. Brazil Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 206. Brazil Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 207. Brazil Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 208. Brazil Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 209. Argentina Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 210. Argentina Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 211. Argentina Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 212. Argentina Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 213. Argentina Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 214. Rest of South America Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 215. Rest of South America Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 216. Rest of South America Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 217. Rest of South America Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 218. Rest of South America Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 219. Asia Pacific Melanoma Therapeutics Sales, by Country k Tons (2013-2018)
  • Table 220. Asia Pacific Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 221. Asia Pacific Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 222. Asia Pacific Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 223. Asia Pacific Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 224. Asia Pacific Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 225. China Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 226. China Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 227. China Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 228. China Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 229. China Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 230. Japan Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 231. Japan Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 232. Japan Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 233. Japan Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 234. Japan Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 235. India Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 236. India Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 237. India Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 238. India Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 239. India Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 240. South Korea Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 241. South Korea Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 242. South Korea Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 243. South Korea Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 244. South Korea Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 245. Taiwan Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 246. Taiwan Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 247. Taiwan Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 248. Taiwan Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 249. Taiwan Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 250. Australia Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 251. Australia Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 252. Australia Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 253. Australia Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 254. Australia Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 255. Rest of Asia-Pacific Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 256. Rest of Asia-Pacific Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 257. Rest of Asia-Pacific Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 258. Rest of Asia-Pacific Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 259. Rest of Asia-Pacific Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 260. Europe Melanoma Therapeutics Sales, by Country k Tons (2013-2018)
  • Table 261. Europe Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 262. Europe Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 263. Europe Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 264. Europe Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 265. Europe Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 266. Germany Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 267. Germany Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 268. Germany Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 269. Germany Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 270. Germany Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 271. France Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 272. France Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 273. France Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 274. France Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 275. France Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 276. Italy Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 277. Italy Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 278. Italy Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 279. Italy Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 280. Italy Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 281. United Kingdom Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 282. United Kingdom Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 283. United Kingdom Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 284. United Kingdom Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 285. United Kingdom Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 286. Netherlands Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 287. Netherlands Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 288. Netherlands Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 289. Netherlands Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 290. Netherlands Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 291. Rest of Europe Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 292. Rest of Europe Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 293. Rest of Europe Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 294. Rest of Europe Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 295. Rest of Europe Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 296. MEA Melanoma Therapeutics Sales, by Country k Tons (2013-2018)
  • Table 297. MEA Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 298. MEA Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 299. MEA Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 300. MEA Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 301. MEA Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 302. Middle East Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 303. Middle East Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 304. Middle East Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 305. Middle East Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 306. Middle East Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 307. Africa Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 308. Africa Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 309. Africa Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 310. Africa Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 311. Africa Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 312. North America Melanoma Therapeutics Sales, by Country k Tons (2013-2018)
  • Table 313. North America Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 314. North America Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 315. North America Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 316. North America Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 317. North America Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 318. United States Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 319. United States Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 320. United States Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 321. United States Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 322. United States Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 323. Canada Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 324. Canada Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 325. Canada Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 326. Canada Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 327. Canada Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 328. Mexico Melanoma Therapeutics Sales, by Drugs k Tons (2013-2018)
  • Table 329. Mexico Melanoma Therapeutics Sales, by Therapy k Tons (2013-2018)
  • Table 330. Mexico Melanoma Therapeutics Sales, by Stages k Tons (2013-2018)
  • Table 331. Mexico Melanoma Therapeutics Sales, by Cancer Type k Tons (2013-2018)
  • Table 332. Mexico Melanoma Therapeutics Sales, by Diagnosis k Tons (2013-2018)
  • Table 333. Company Basic Information, Sales Area and Its Competitors
  • Table 334. Company Basic Information, Sales Area and Its Competitors
  • Table 335. Company Basic Information, Sales Area and Its Competitors
  • Table 336. Company Basic Information, Sales Area and Its Competitors
  • Table 337. Company Basic Information, Sales Area and Its Competitors
  • Table 338. Company Basic Information, Sales Area and Its Competitors
  • Table 339. Company Basic Information, Sales Area and Its Competitors
  • Table 340. Company Basic Information, Sales Area and Its Competitors
  • Table 341. Company Basic Information, Sales Area and Its Competitors
  • Table 342. Melanoma Therapeutics: by Drugs(USD Million)
  • Table 343. Melanoma Therapeutics Opdivo , by Region USD Million (2019-2024)
  • Table 344. Melanoma Therapeutics Yervoy , by Region USD Million (2019-2024)
  • Table 345. Melanoma Therapeutics Mekinist+Tafinlar , by Region USD Million (2019-2024)
  • Table 346. Melanoma Therapeutics Keytruda , by Region USD Million (2019-2024)
  • Table 347. Melanoma Therapeutics Cotellic , by Region USD Million (2019-2024)
  • Table 348. Melanoma Therapeutics Zelboraf , by Region USD Million (2019-2024)
  • Table 349. Melanoma Therapeutics Imlygic , by Region USD Million (2019-2024)
  • Table 350. Melanoma Therapeutics Generics , by Region USD Million (2019-2024)
  • Table 351. Melanoma Therapeutics: by Therapy(USD Million)
  • Table 352. Melanoma Therapeutics Chemotherapy , by Region USD Million (2019-2024)
  • Table 353. Melanoma Therapeutics Immunotherapy , by Region USD Million (2019-2024)
  • Table 354. Melanoma Therapeutics Targeted Therapy , by Region USD Million (2019-2024)
  • Table 355. Melanoma Therapeutics Radiation Therapy , by Region USD Million (2019-2024)
  • Table 356. Melanoma Therapeutics: by Stages(USD Million)
  • Table 357. Melanoma Therapeutics Stage 0 (Melanoma in Situ) , by Region USD Million (2019-2024)
  • Table 358. Melanoma Therapeutics Stage I , by Region USD Million (2019-2024)
  • Table 359. Melanoma Therapeutics Stage II , by Region USD Million (2019-2024)
  • Table 360. Melanoma Therapeutics Stage III , by Region USD Million (2019-2024)
  • Table 361. Melanoma Therapeutics Stage IV , by Region USD Million (2019-2024)
  • Table 362. Melanoma Therapeutics: by Cancer Type(USD Million)
  • Table 363. Melanoma Therapeutics Nodular Melanoma , by Region USD Million (2019-2024)
  • Table 364. Melanoma Therapeutics Acral Lentiginous Melanoma , by Region USD Million (2019-2024)
  • Table 365. Melanoma Therapeutics Superficial Spreading Melanoma , by Region USD Million (2019-2024)
  • Table 366. Melanoma Therapeutics Others , by Region USD Million (2019-2024)
  • Table 367. Melanoma Therapeutics: by Diagnosis(USD Million)
  • Table 368. Melanoma Therapeutics Ultrasound , by Region USD Million (2019-2024)
  • Table 369. Melanoma Therapeutics Blood Tests , by Region USD Million (2019-2024)
  • Table 370. Melanoma Therapeutics Dermatoscopy , by Region USD Million (2019-2024)
  • Table 371. Melanoma Therapeutics CT scan , by Region USD Million (2019-2024)
  • Table 372. Melanoma Therapeutics Others , by Region USD Million (2019-2024)
  • Table 373. South America Melanoma Therapeutics, by Country USD Million (2019-2024)
  • Table 374. South America Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 375. South America Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 376. South America Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 377. South America Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 378. South America Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 379. Brazil Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 380. Brazil Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 381. Brazil Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 382. Brazil Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 383. Brazil Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 384. Argentina Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 385. Argentina Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 386. Argentina Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 387. Argentina Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 388. Argentina Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 389. Rest of South America Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 390. Rest of South America Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 391. Rest of South America Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 392. Rest of South America Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 393. Rest of South America Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 394. Asia Pacific Melanoma Therapeutics, by Country USD Million (2019-2024)
  • Table 395. Asia Pacific Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 396. Asia Pacific Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 397. Asia Pacific Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 398. Asia Pacific Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 399. Asia Pacific Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 400. China Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 401. China Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 402. China Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 403. China Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 404. China Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 405. Japan Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 406. Japan Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 407. Japan Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 408. Japan Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 409. Japan Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 410. India Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 411. India Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 412. India Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 413. India Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 414. India Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 415. South Korea Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 416. South Korea Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 417. South Korea Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 418. South Korea Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 419. South Korea Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 420. Taiwan Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 421. Taiwan Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 422. Taiwan Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 423. Taiwan Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 424. Taiwan Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 425. Australia Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 426. Australia Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 427. Australia Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 428. Australia Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 429. Australia Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 430. Rest of Asia-Pacific Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 431. Rest of Asia-Pacific Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 432. Rest of Asia-Pacific Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 433. Rest of Asia-Pacific Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 434. Rest of Asia-Pacific Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 435. Europe Melanoma Therapeutics, by Country USD Million (2019-2024)
  • Table 436. Europe Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 437. Europe Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 438. Europe Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 439. Europe Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 440. Europe Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 441. Germany Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 442. Germany Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 443. Germany Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 444. Germany Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 445. Germany Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 446. France Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 447. France Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 448. France Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 449. France Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 450. France Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 451. Italy Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 452. Italy Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 453. Italy Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 454. Italy Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 455. Italy Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 456. United Kingdom Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 457. United Kingdom Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 458. United Kingdom Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 459. United Kingdom Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 460. United Kingdom Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 461. Netherlands Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 462. Netherlands Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 463. Netherlands Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 464. Netherlands Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 465. Netherlands Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 466. Rest of Europe Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 467. Rest of Europe Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 468. Rest of Europe Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 469. Rest of Europe Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 470. Rest of Europe Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 471. MEA Melanoma Therapeutics, by Country USD Million (2019-2024)
  • Table 472. MEA Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 473. MEA Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 474. MEA Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 475. MEA Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 476. MEA Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 477. Middle East Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 478. Middle East Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 479. Middle East Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 480. Middle East Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 481. Middle East Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 482. Africa Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 483. Africa Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 484. Africa Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 485. Africa Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 486. Africa Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 487. North America Melanoma Therapeutics, by Country USD Million (2019-2024)
  • Table 488. North America Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 489. North America Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 490. North America Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 491. North America Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 492. North America Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 493. United States Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 494. United States Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 495. United States Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 496. United States Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 497. United States Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 498. Canada Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 499. Canada Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 500. Canada Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 501. Canada Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 502. Canada Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 503. Mexico Melanoma Therapeutics, by Drugs USD Million (2019-2024)
  • Table 504. Mexico Melanoma Therapeutics, by Therapy USD Million (2019-2024)
  • Table 505. Mexico Melanoma Therapeutics, by Stages USD Million (2019-2024)
  • Table 506. Mexico Melanoma Therapeutics, by Cancer Type USD Million (2019-2024)
  • Table 507. Mexico Melanoma Therapeutics, by Diagnosis USD Million (2019-2024)
  • Table 508. Melanoma Therapeutics Sales: by Drugs(k Tons)
  • Table 509. Melanoma Therapeutics Sales Opdivo , by Region k Tons (2019-2024)
  • Table 510. Melanoma Therapeutics Sales Yervoy , by Region k Tons (2019-2024)
  • Table 511. Melanoma Therapeutics Sales Mekinist+Tafinlar , by Region k Tons (2019-2024)
  • Table 512. Melanoma Therapeutics Sales Keytruda , by Region k Tons (2019-2024)
  • Table 513. Melanoma Therapeutics Sales Cotellic , by Region k Tons (2019-2024)
  • Table 514. Melanoma Therapeutics Sales Zelboraf , by Region k Tons (2019-2024)
  • Table 515. Melanoma Therapeutics Sales Imlygic , by Region k Tons (2019-2024)
  • Table 516. Melanoma Therapeutics Sales Generics , by Region k Tons (2019-2024)
  • Table 517. Melanoma Therapeutics Sales: by Therapy(k Tons)
  • Table 518. Melanoma Therapeutics Sales Chemotherapy , by Region k Tons (2019-2024)
  • Table 519. Melanoma Therapeutics Sales Immunotherapy , by Region k Tons (2019-2024)
  • Table 520. Melanoma Therapeutics Sales Targeted Therapy , by Region k Tons (2019-2024)
  • Table 521. Melanoma Therapeutics Sales Radiation Therapy , by Region k Tons (2019-2024)
  • Table 522. Melanoma Therapeutics Sales: by Stages(k Tons)
  • Table 523. Melanoma Therapeutics Sales Stage 0 (Melanoma in Situ) , by Region k Tons (2019-2024)
  • Table 524. Melanoma Therapeutics Sales Stage I , by Region k Tons (2019-2024)
  • Table 525. Melanoma Therapeutics Sales Stage II , by Region k Tons (2019-2024)
  • Table 526. Melanoma Therapeutics Sales Stage III , by Region k Tons (2019-2024)
  • Table 527. Melanoma Therapeutics Sales Stage IV , by Region k Tons (2019-2024)
  • Table 528. Melanoma Therapeutics Sales: by Cancer Type(k Tons)
  • Table 529. Melanoma Therapeutics Sales Nodular Melanoma , by Region k Tons (2019-2024)
  • Table 530. Melanoma Therapeutics Sales Acral Lentiginous Melanoma , by Region k Tons (2019-2024)
  • Table 531. Melanoma Therapeutics Sales Superficial Spreading Melanoma , by Region k Tons (2019-2024)
  • Table 532. Melanoma Therapeutics Sales Others , by Region k Tons (2019-2024)
  • Table 533. Melanoma Therapeutics Sales: by Diagnosis(k Tons)
  • Table 534. Melanoma Therapeutics Sales Ultrasound , by Region k Tons (2019-2024)
  • Table 535. Melanoma Therapeutics Sales Blood Tests , by Region k Tons (2019-2024)
  • Table 536. Melanoma Therapeutics Sales Dermatoscopy , by Region k Tons (2019-2024)
  • Table 537. Melanoma Therapeutics Sales CT scan , by Region k Tons (2019-2024)
  • Table 538. Melanoma Therapeutics Sales Others , by Region k Tons (2019-2024)
  • Table 539. South America Melanoma Therapeutics Sales, by Country k Tons (2019-2024)
  • Table 540. South America Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 541. South America Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 542. South America Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 543. South America Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 544. South America Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 545. Brazil Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 546. Brazil Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 547. Brazil Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 548. Brazil Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 549. Brazil Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 550. Argentina Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 551. Argentina Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 552. Argentina Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 553. Argentina Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 554. Argentina Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 555. Rest of South America Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 556. Rest of South America Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 557. Rest of South America Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 558. Rest of South America Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 559. Rest of South America Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 560. Asia Pacific Melanoma Therapeutics Sales, by Country k Tons (2019-2024)
  • Table 561. Asia Pacific Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 562. Asia Pacific Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 563. Asia Pacific Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 564. Asia Pacific Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 565. Asia Pacific Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 566. China Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 567. China Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 568. China Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 569. China Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 570. China Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 571. Japan Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 572. Japan Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 573. Japan Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 574. Japan Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 575. Japan Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 576. India Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 577. India Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 578. India Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 579. India Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 580. India Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 581. South Korea Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 582. South Korea Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 583. South Korea Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 584. South Korea Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 585. South Korea Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 586. Taiwan Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 587. Taiwan Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 588. Taiwan Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 589. Taiwan Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 590. Taiwan Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 591. Australia Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 592. Australia Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 593. Australia Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 594. Australia Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 595. Australia Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 596. Rest of Asia-Pacific Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 597. Rest of Asia-Pacific Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 598. Rest of Asia-Pacific Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 599. Rest of Asia-Pacific Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 600. Rest of Asia-Pacific Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 601. Europe Melanoma Therapeutics Sales, by Country k Tons (2019-2024)
  • Table 602. Europe Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 603. Europe Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 604. Europe Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 605. Europe Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 606. Europe Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 607. Germany Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 608. Germany Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 609. Germany Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 610. Germany Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 611. Germany Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 612. France Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 613. France Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 614. France Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 615. France Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 616. France Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 617. Italy Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 618. Italy Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 619. Italy Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 620. Italy Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 621. Italy Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 622. United Kingdom Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 623. United Kingdom Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 624. United Kingdom Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 625. United Kingdom Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 626. United Kingdom Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 627. Netherlands Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 628. Netherlands Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 629. Netherlands Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 630. Netherlands Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 631. Netherlands Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 632. Rest of Europe Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 633. Rest of Europe Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 634. Rest of Europe Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 635. Rest of Europe Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 636. Rest of Europe Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 637. MEA Melanoma Therapeutics Sales, by Country k Tons (2019-2024)
  • Table 638. MEA Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 639. MEA Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 640. MEA Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 641. MEA Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 642. MEA Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 643. Middle East Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 644. Middle East Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 645. Middle East Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 646. Middle East Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 647. Middle East Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 648. Africa Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 649. Africa Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 650. Africa Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 651. Africa Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 652. Africa Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 653. North America Melanoma Therapeutics Sales, by Country k Tons (2019-2024)
  • Table 654. North America Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 655. North America Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 656. North America Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 657. North America Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 658. North America Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 659. United States Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 660. United States Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 661. United States Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 662. United States Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 663. United States Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 664. Canada Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 665. Canada Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 666. Canada Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 667. Canada Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 668. Canada Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 669. Mexico Melanoma Therapeutics Sales, by Drugs k Tons (2019-2024)
  • Table 670. Mexico Melanoma Therapeutics Sales, by Therapy k Tons (2019-2024)
  • Table 671. Mexico Melanoma Therapeutics Sales, by Stages k Tons (2019-2024)
  • Table 672. Mexico Melanoma Therapeutics Sales, by Cancer Type k Tons (2019-2024)
  • Table 673. Mexico Melanoma Therapeutics Sales, by Diagnosis k Tons (2019-2024)
  • Table 674. Research Programs/Design for This Report
  • Table 675. Key Data Information from Secondary Sources
  • Table 676. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Melanoma Therapeutics: by Drugs USD Million (2013-2018)
  • Figure 5. Global Melanoma Therapeutics: by Therapy USD Million (2013-2018)
  • Figure 6. Global Melanoma Therapeutics: by Stages USD Million (2013-2018)
  • Figure 7. Global Melanoma Therapeutics: by Cancer Type USD Million (2013-2018)
  • Figure 8. Global Melanoma Therapeutics: by Diagnosis USD Million (2013-2018)
  • Figure 9. South America Melanoma Therapeutics Share (%), by Country
  • Figure 10. Asia Pacific Melanoma Therapeutics Share (%), by Country
  • Figure 11. Europe Melanoma Therapeutics Share (%), by Country
  • Figure 12. MEA Melanoma Therapeutics Share (%), by Country
  • Figure 13. North America Melanoma Therapeutics Share (%), by Country
  • Figure 14. Global Melanoma Therapeutics: by Drugs k Tons (2013-2018)
  • Figure 15. Global Melanoma Therapeutics: by Therapy k Tons (2013-2018)
  • Figure 16. Global Melanoma Therapeutics: by Stages k Tons (2013-2018)
  • Figure 17. Global Melanoma Therapeutics: by Cancer Type k Tons (2013-2018)
  • Figure 18. Global Melanoma Therapeutics: by Diagnosis k Tons (2013-2018)
  • Figure 19. South America Melanoma Therapeutics Share (%), by Country
  • Figure 20. Asia Pacific Melanoma Therapeutics Share (%), by Country
  • Figure 21. Europe Melanoma Therapeutics Share (%), by Country
  • Figure 22. MEA Melanoma Therapeutics Share (%), by Country
  • Figure 23. North America Melanoma Therapeutics Share (%), by Country
  • Figure 24. Global Melanoma Therapeutics share by Players 2018 (%)
  • Figure 25. Global Melanoma Therapeutics share by Players (Top 3) 2018(%)
  • Figure 26. Global Melanoma Therapeutics share by Players (Top 5) 2018(%)
  • Figure 27. BCG Matrix for key Companies
  • Figure 28. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. AstraZeneca plc (United Kingdom) Revenue: by Geography 2018
  • Figure 30. Amgen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Amgen, Inc. (United States) Revenue: by Geography 2018
  • Figure 32. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2018
  • Figure 34. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 35. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2018
  • Figure 36. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 37. Novartis International AG (Switzerland) Revenue: by Geography 2018
  • Figure 38. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Merck & Co., Inc. (United States) Revenue: by Geography 2018
  • Figure 40. Daiichi Sankyo Company, Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 41. Daiichi Sankyo Company, Limited (Japan) Revenue: by Geography 2018
  • Figure 42. AB Sciences (France) Revenue, Net Income and Gross profit
  • Figure 43. AB Sciences (France) Revenue: by Geography 2018
  • Figure 44. Vical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 45. Vical, Inc. (United States) Revenue: by Geography 2018
  • Figure 46. Global Melanoma Therapeutics: by Drugs USD Million (2019-2024)
  • Figure 47. Global Melanoma Therapeutics: by Therapy USD Million (2019-2024)
  • Figure 48. Global Melanoma Therapeutics: by Stages USD Million (2019-2024)
  • Figure 49. Global Melanoma Therapeutics: by Cancer Type USD Million (2019-2024)
  • Figure 50. Global Melanoma Therapeutics: by Diagnosis USD Million (2019-2024)
  • Figure 51. South America Melanoma Therapeutics Share (%), by Country
  • Figure 52. Asia Pacific Melanoma Therapeutics Share (%), by Country
  • Figure 53. Europe Melanoma Therapeutics Share (%), by Country
  • Figure 54. MEA Melanoma Therapeutics Share (%), by Country
  • Figure 55. North America Melanoma Therapeutics Share (%), by Country
  • Figure 56. Global Melanoma Therapeutics: by Drugs k Tons (2019-2024)
  • Figure 57. Global Melanoma Therapeutics: by Therapy k Tons (2019-2024)
  • Figure 58. Global Melanoma Therapeutics: by Stages k Tons (2019-2024)
  • Figure 59. Global Melanoma Therapeutics: by Cancer Type k Tons (2019-2024)
  • Figure 60. Global Melanoma Therapeutics: by Diagnosis k Tons (2019-2024)
  • Figure 61. South America Melanoma Therapeutics Share (%), by Country
  • Figure 62. Asia Pacific Melanoma Therapeutics Share (%), by Country
  • Figure 63. Europe Melanoma Therapeutics Share (%), by Country
  • Figure 64. MEA Melanoma Therapeutics Share (%), by Country
  • Figure 65. North America Melanoma Therapeutics Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • AstraZeneca plc (United Kingdom)
  • Amgen, Inc. (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Bristol-Myers Squibb Company (United States)
  • Novartis International AG (Switzerland)
  • Merck & Co., Inc. (United States)
  • Daiichi Sankyo Company, Limited (Japan)
  • AB Sciences (France)
  • Vical, Inc. (United States)
Additional players considered in the study are as follows:
Pfizer, Inc. (United States) , GlaxoSmithKline, plc. (United Kingdom) , Eisai Co., Ltd. (Japan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation